January 2, 2024 02:14 PM EST
Pharma

Bey­for­tus ap­proved in Chi­na to pro­tect in­fants from RSV; Il­lu­mi­na in­vestor files class ac­tion suit

Nicole DeFeudis

Editor

Lia DeGroot

As­traZeneca and Sanofi’s Bey­for­tus won an ap­proval in Chi­na to pre­vent RSV low­er res­pi­ra­to­ry tract in­fec­tion in new­borns and in­fants dur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

A service from the Financial Times